PHAT Earnings — Phathom Pharmaceuticals, Inc. Common Stock Post-ER Performance | BigEarnings
PHAT — Phathom Pharmaceuticals, Inc. Common Stock
XNAS · Healthcare · Biotechnology
Price$9.59
Market Cap$764.9M
P/E—
52W Range$4.25 – $18.31
Next Earnings2026-08-06
About Phathom Pharmaceuticals, Inc. Common Stock
Phathom Pharmaceuticals Inc operates as a clinical-stage biopharmaceutical company. The firm is focused on developing and commercializing novel treatments for gastrointestinal, or GI, diseases. Its product comprises vonoprazan, an oral small-molecule potassium competitive acid blocker medicine that blocks acid secretion in the stomach. Vonoprazan shows rapid, potent, and durable anti-secretory effects and has demonstrated clinical benefits in the treatment of gastroesophageal reflux disease, and in combination with antibiotics for the treatment of Helicobacter pylori infection.